Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
Inhaled Doxorubicin Plus IV Docetaxel and Cisplatin in Patients with Non-Small-Cell Lung Carcinoma (NSCLC)
This study is currently recruiting patients.
Sponsored by: | Zivena |
---|---|
Information provided by: | Zivena |
Purpose
This study is intended to show whether inhaled chemotherapy can be added to a standard IV chemotherapy regime, to investigate the additional toxicities and to show initial evidence of efficacy of the combination.
Condition | Treatment or Intervention | Phase |
---|---|---|
NSCLC |
Drug: Doxorubicin HCl Inhalation Solution Drug: Docetaxel Drug: Cisplatin |
Phase I Phase II |
MedlinePlus related topics: Cancer; Cancer Alternative Therapy; Lung Cancer; Respiratory Diseases
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title: Phase I/II Study of Inhaled Doxorubicin Plus IV Docetaxel and Cisplatin in Patients with Locally Advanced or Metastatic Unresectable Non Small Cell Lung Cancer
Expected Total Enrollment: 30
Study start: January 2004
Primary Objective of Phase I
Primary Objective of Phase II
Secondary Objective
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
Exclusion Criteria:
Location and Contact Information
More Information
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |